Stimulation of collateral artery growth: A potential treatment for peripheral artery disease

Expert Review of Cardiovascular Therapy

Volumn 2, Issue 4, 2004, Pages 581-588

  Schirmer, Stephan H ^a   van Royen, Niels ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Angiogenesis; Arteriogenesis; Collateral artery growth; Cytokines; FGF; GM CSF; Growth factors; MCP 1; TGF 1; VEGF

Indexed keywords

ADENOVIRUS VECTOR; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA CHEMOKINE; CILOSTAZOL; CYTOKINE; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; GLUCOSE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; NAKED DNA; PLACEBO; PLASMID DNA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165;

ANGIOGENESIS; ARTERY DISEASE; BEHAVIOR MODIFICATION; BLOOD VESSEL OCCLUSION; BYPASS SURGERY; CELL BASED GENE THERAPY; CLAUDICATION; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE COURSE; DRUG MECHANISM; EDEMA; GENE DELIVERY SYSTEM; GENE TRANSFER; GLUCOSE BLOOD LEVEL; GROWTH STIMULATION; HUMAN; HYPOXIA; LIMB ISCHEMIA; MONOCYTE; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL CIRCULATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINURIA; REVIEW; STEM CELL TRANSPLANTATION; TISSUE OXYGENATION; WALKING;

ARTERIAL OCCLUSIVE DISEASES; COLLATERAL CIRCULATION; FIBROBLAST GROWTH FACTOR 2; GENE TRANSFER TECHNIQUES; HUMANS; PERIPHERAL VASCULAR DISEASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 4043092854     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.2.4.581     Document Type: Review

References (74)

1. Murray CJ, Lopez AD. Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study. Lancet 349, 1436-1442 (1997).
2. Ouriel K. Peripheral arterial disease. Lancet 358, 1257-1264 (2001).
3. Criqui MH, Langer RD, Fronek A et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N. Engl. J. Med. 326, 381-386 (1992).
4. Hiatt WR. Pharmacologic therapy for peripheral arterial disease and claudication. J. Vasc. Surg. 36, 1283-1291 (2002).
5. Dean SM. Pharmacologic treatment for intermittent claudication. Vasc. Med. 7, 301-309 (2002).
6. Molloy KJ, Nasim. A, London NJ et al. Percutaneous transluminal angioplasty in the treatment of critical limb ischemia. J. Endovasc. Ther. 10, 298-303 (2003).
7. Watson HR, Belcher G, Horrocks M. Reintervention as a clinical trial end point after peripheral arterial bypass surgery. Br. J. Surg. 88, 1376-1381 (2001).
8. Matsi PJ, Manninen HI, Soder HK, Mustonen P, Kouri J. Percutaneous transluminal angioplasty in femoral artery occlusions: primary and long-term results in 107 claudicant patients using femoral and popliteal catheterization techniques. Clin. Radiol. 50, 237-244 (1995).
9. Lower R. Early science in Oxford. In: Oxford. Oxford University Press, Oxford, UK (1932).
10. Fulton WMF. The Coronary Arteries. Charles C Thomas Publishers, IL, USA (1965).
11. Schaper W. On arteriogenesis - a reply. Basic Res. Cardiol. 98, 183-184 (2003).
12. Risau W. Mechanisms of angiogenesis. Nature 386, 671-674 (1997).
13. Buschmann I, Schaper W. Arteriogenesis versus angiogenesis: two mechanisms of vessel growth. News Physiol. Sci. 14, 121-125. (1999).
14. van Royen N, Piek JJ, Buschmann I, Hoefer I, Voskuil M, Schaper W. Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease. Cardiovasc. Res. 49, 543-553. (2001).
15. Helisch A, Schaper W. Angiogenesis and arteriogenesis - not yet for prescription. Z. Kardiol. 89, 239-244 (2000).
16. Niebauer J, Cooke JP. Cardiovascular effects of exercise: role of endothelial shear stress. J. Am. Coll. Cardiol. 28, 1652-1660 (1996).
17. Shyy YJ, Hsieh HJ, Usami S, Chien S. Fluid shear stress induces a biphasic response of human monocyte chemotactic protein 1 gene expression in vascular endothelium. Proc. Natl Acad Sci. USA 91, 4678-4682. (1994).
18. Randolph GJ, Furie MB. A soluble gradient of endogenous monocyte chemoattractant protein-1 promotes the transendothelial migration of monocytes in vitro. J. Immunol. 155, 3610-3618 (1995).
19. Scholz D, Ito W, Fleming I et al. Ultrastructure and molecular histology of rabbit hind-limb collateral artery growth (arteriogenesis). Virchows Arch. 436, 257-270 (2000).
20. Arras M, Ito WD, Scholz D, Winkler B, Schaper J, Schaper W. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J. Clin. Invest. 101, 40-50. (1998).
21. Cai WJ, Koltai S, Kocsis E et al. Remodeling of the adventitia during coronary arteriogenesis. Am. J. Physiol. Heart Circ. Physiol. 284, H31-H40 (2003).
22. Malik N, Greenfield BW, Wahl AF, Kiener PA. Activation of human monocytes through CD40 induces matrix metalloproteinases. J. Immunol. 156, 3952-3960 (1996).
23. Hoefer IE, van Royen N, Rectenwald JE et al. Direct evidence for tumor necrosis factor-α signaling in arteriogenesis. Circulation 105, 1639-1641 (2002).
24. Scholz D, Ziegelhoeffer T, Helisch A et al. Contribution of arteriogenesis and angiogenesis to postocclusive hindlimb perfusion in mice. J. Mol. Cell. Cardiol. 34, 775-787 (2002).
25. Hoefer IE, Voskuil M, van Royen N. Arteriogenesis in mice. In: The Physiological Genomics of the Critically Ill Mouse. Ince C (Ed.), Kluwer Academic Publishers, MA, USA (2003).
26. Van Royen N, Voskuil M, Hoefer I et al. CD44 regulates arteriogenesis in mice and is differentially expressed in patients with poor and good collateralization. Circulation 109(13), 1647-1652 (2004).
27. Hoefer IE, van Royen N, Buschmann IR, Piek JJ, Schaper W. Time course of arteriogenesis following femoral artery occlusion in the rabbit. Cardiovasc. Res. 49, 609-617 (2001).
28. Deindl E, Buschmann I, Hoefer IE et al. Role of ischemia and of hypoxia-inducible genes in arteriogenesis after femoral artery occlusion in the rabbit. Circ. Res. 89, 779-786 (2001).
29. Pu LQ, Jackson S, Lachapelle KJ et al. A persistent hindlimb ischemia model in the rabbit. J. Invest. Surg. 7, 49-60 (1994).
30. Buschmann IR, Voskuil M, van Royen N et al. Invasive and noninvasive evaluation of spontaneous arteriogenesis in a novel porcine model for peripheral arterial obstructive disease. Atherosclerosis 167, 33-43 (2003).
31. Voskuil M, van Royen N, Hoefer IE et al. Modulation of collateral artery growth in a porcine hindlimb ligation model using MCP-1. Am. J. Physiol. Heart Circ. Physiol. 284, H1422-H1428 (2003).
32. Ito WD, Arras M, Winkler B, Scholz D, Schaper J, Schaper W. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ. Res. 80, 829-837 (1997).
33. van Royen N, Hoefer I, Buschmann I et al. Effects of local MCP-1 protein therapy on the development of the collateral circulation and atherosclerosis in Watanabe-hyperlipidemic rabbits. Cardiovasc Res. 57, 178-185 (2003).
34. van Royen N, Hoefer I, Bottinger M et al. Local monocyte chemoattractant protein-1 therapy increases collateral artery formation in apolipoprotein E-deficient mice but induces systemic monocytic CD11b expression, neointimal formation and plaque progression. Circ. Res. 92, 218-225 (2003).
35. Buschmann IR, Hoefer IE, van Royen N et al. GM-CSF: a strong arteriogenic factor acting by amplification of monocyte function. Atherosclerosis 159, 343-356 (2001).
36. Flad HD, Grage-Griebenow E, Scheuerer B et al. The role of cytokines in monocyte apoptosis. Res. Immunol. 149, 733-736 (1998).
37. van Royen N, Hoefer I, Buschmarm I et al. Exogenous application of transforming growth factor-β1 stimulates arteriogenesis in the peripheral circulation. Faseb J. 16, 432-434. (2002).
38. Ohno M, Cooke JP, Dzau VJ, Gibbons GH. Fluid shear stress induces endothelial transforming growth factor-β1 transcription and production. Modulation by potassium channel blockade. J. Clin. Invest. 95, 1363-1369 (1995).
39. Wahl SM, McCartney-Francis N, Allen JB, Dougherty EB, Dougherty SF. Macrophage production of TGF-β and regulation by TGF-β. Ann. NY Acad Sci. 593, 188-196 (1990).
40. Boengler K, Pipp F, Fernandez B, Ziegelhoeffer T, Schaper W, Deindl E. Arteriogenesis is associated with an induction of the cardiac ankyrin repeat protein (CARP). Cardiovasc. Res. 59, 573-581 (2003).
41. Epstein SE, Fuchs S, Zhou YF, Baffour R, Kornowski R. Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results and potential hazards. Cardiovasc. Res. 49, 532-542 (2001).
42. Deindl E, Hoefer IE, Fernandez B et al. Involvement of the fibroblast growth factor system in adaptive and chemokine-induced arteriogenesis. Circ Res. 92, 561-568 (2003).
43. Doukas J, Blease K, Craig D et al. Delivery of FGF genes to wound repair cells enhances arteriogenesis and myogenesis in skeletal muscle. Mol. Ther. 5, 517-527 (2002).
44. Ueno H, Li JJ, Masuda S, Qi Z, Yamamoto H, Takeshita A. Adenovirus-mediated expression of the secreted form of basic fibroblast growth factor (FGF-2) induces cellular proliferation and angiogenesis in vivo. Arterioscler. Thromb. Vasc. Biol. 17, 2453-2460 (1997).
45. Yang HT, Deschenes MR, Ogilvie RW, Terjung RL. Basic fibroblast growth factor increases collateral blood flow in rats with femoral arterial ligation. Circ. Res. 79, 62-69 (1996).
46. Rissanen TT, Markkanen JE, Arve K et al. Fibroblast growth factor 4 induces vascular permeability, angiogenesis and arteriogenesis in a rabbit hindlimb ischaemia model. Faseb J. 17, 100-102 (2003).
47. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971).
48. Hershey JC, Baskin EP, Corcoran HA et al. Vascular endothelial growth factor stimulates angiogenesis without improving collateral blood flow following hindlimb ischemia in rabbits. Heart Vessels 18, 142-149 (2003).
49. Crottogini A, Meckert PC, Vera Janavel G et al. Arteriogenesis induced by intramyocardial vascular endothelial growth factor 165 gene transfer in chronically ischemic pigs. Hum. Gene Ther. 14, 1307-1318 (2003).
50. Heil M, Clauss M, Suzuki K et al. Vascular endothelial growth factor (VEGF) stimulates monocyte migration through endothelial monolayers via increased integrin expression. Eur. J. Cell. Biol. 79, 850-857 (2000).
51. Pipp F, Heil M, Issbrucker K et al. VEGFR-1-selective VEGF homologue PIGF is arteriogenic: evidence for a monocyte-mediated mechanism. Circ. Res. 92, 378-385 (2003).
52. Asahara T, Masuda H, Takahashi T et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 85, 221-228 (1999).
53. Khurana R, Simons M. Endothelial progenitor cells: precursors for angiogenesis. Semin. Thorac. Cardiovasc. Surg. 15, 250-258 (2003).
54. Kamihata H, Matsubara H, Nishiue T et al. Improvement of collateral perfusion and regional function by implantation of peripheral blood mononuclear cells into ischemic hibernating myocardium. Arterioscler. Thromb. Vasc. Biol. 22, 1804-1810 (2002).
55. Barbash IM, Chouraqui P, Baron J et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration and body distribution. Circulation 108, 863-868 (2003).
56. Kamihata H, Matsubara H, Nishiue T et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands and cytokines. Circulation 104, 1046-1052 (2001).
57. Ross R, Harker L. Hyperlipidemia and atherosclerosis. Science 193, 1094-1100 (1976).
58. Rehman J, Li J, Orschell CM, March KL. Peripheral blood 'endothelial progenitor cells' are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 107, 1164-1169 (2003).
59. Ziegelhoeffer T, Scholz D, Friedrich C et al. Inhibition of collateral artery growth by mibefradil: possible role of volume-regulated chloride channels. Endothelium 10, 237-246 (2003).
60. Isner JM, Pieczek A, Schainfeld R et al. Clinical evidence ofangiogenesis after arterial gene transfer of phVEGF165 in patient with ischemic limb. Lancet 348, 370-374 (1996).
61. Baumgartner I, Pieczek A, Manor O et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischaemia. Circulation 97, 1114-1123 (1998).
62. Mohler ER 3rd, Rajagopalan S, Olin JW et al. Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischaemia: safety results from a Phase I trial. Vasc. Med. 8, 9-13 (2003).
63. Henry TD, Annex BH, McKendall GR et al. The VIVA Trial: Vascular endothelial growth factor in Ischaemia for Vascular Angiogenesis. Circulation 107, 1359-1365 (2003).
64. Rajagopalan S, Mohler ER 3rd, Lederman RJ et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a Phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108, 1933-1938 (2003).
65. Lazarous DF, Unger EF, Epstein SE et al. Basic fibroblast growth factor in patients with intermittent claudication: results of a Phase I trial. J. Am. Coll. Cardiol. 36, 1239-1244 (2000).
66. Cooper LT Jr, Hiatt WR, Creager MA et al. Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication. Vasc. Med. 6, 235-239 (2001).
67. Comerota AJ, Throm RC, Miller KA et al. Naked plasmid DNA encoding fibroblast growth factor Type 1 for the treatment of end stage unreconstructible lower extremity ischemia: preliminary results of a Phase I trial. J. Vasc. Surg. 35, 930-936 (2002).
68. Lederman RJ, Mendelsohn FO, Anderson RD et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomized trial. Lancet 359, 2053-2058 (2002).
69. Seiler C, Pohl T, Wustmann K et al. Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation 104, 2012-2017 (2001).
70. van Royen N, Piek JJ, Legemate DA et al. Design of the START-trial: STimulation of ARTeriogenesis using subcutaneous application of GM-CSF as a new treatment for peripheral vascular disease. A randomized, double-blind, placebo-controlled trial. Vasc. Med. 8, 191-196 (2003).
71. Heil M, Ziegelhoeffer T, Mees B, Schaper W. A different outlook on the role of bone marrow stem cells in vascular growth: bone marrow delivers software not hardware. Circ. Res. 94, 573-574 (2004).
72. Ziegelhoeffer T, Fernandez B, Kostin S et al. Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circ. Res. 94, 230-238 (2004).
73. Tateishi-Yuyama. E, Matsubara H, Murohara T et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 360, 427-435 (2002).
74. Simons M, Bonow RO, Chronos NA et al. Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary. Circulation 102, E73-E86 (2000).